Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells

被引:0
|
作者
Condiotti, R
Nagler, A [1 ]
机构
[1] Hadassah Univ Hosp, Dept Bone Marrow Transplantat, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Israel Natl Cord Blood Bank, IL-91120 Jerusalem, Israel
关键词
interleukin-12; interleukin-2; human umbilical cord blood; natural killer cells; bone marrow; non-major histocompatibility complex-restricted cytotoxicity;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Interleukin (IL)-12, a natural killer (NK) cell stimulatory factor, is a heterodimeric cytokine that is known to be a potent activator of non-major histocompatibility complex-restricted cytotoxicity by peripheral blood-derived NK cells. NK cells (CD3(-)CD16(+)/CD56(+)) represent approximately 15% of human umbilical cord blood mononuclear cells (HUCB MNCs) and are known to be highly sensitive to activation by IL-2. In the present study, we monitored the effect of IL-12 on the cytotoxic activity, proliferation, and phenotypic expression of HUCB-derived resting and IL-2-activated cytotoxic cells and compared these parameters with those of bone marrow (BM)derived cells. Lymphocytes were separated from HUCB by 3% gelatin sedimentation and incubated with IL-12 and/or IL-2 for 18 hours. At effector:target ratios of 40:1 and 20:1, IL-12 (50 U/mL) significantly increased both resting and IL-2-activated NK cell-mediated cytotoxicity in a standard Cr-51-release assay against both NK-sensitive (K562) and NK-resistant (Colo-205) cell lines. In addition, resting and IL-2-activated cytotoxic cells derived from HUCB exhibited superior cytolytic ability compared with BM-derived cells. This increase was observed in resting cells as well as in those that were preincubated with IL-12. Moreover, HUCB-derived cells were found to be more sensitive to IL-12 activation than cytotoxic cells from BM. To evaluate the involvement of accessory cells, NK cells were purified from HUCB using immunomagnetic beads, and these cells were found to have a lower response to treatment with IL-12 than unpurified populations. HUCB MNCs exhibited a nonsignificant increase in proliferation after IL-12 treatment and were better able to respond to IL-12 activation than BM MNCs. Following an 18-hour incubation, IL-12 was able to cause upregulation of CD25 and CD69 activation antigens, whereas no significant change in expression of CD16 and CD56 NK cell surface antigens, CD3 on T cells, or IL-12 receptor was observed. Similarly, IL-12 did not affect NK cell:target cell conjugation as assessed by fluorescence-activated cell sorting. Our results indicate that HUCB-derived NK-mediated cytotoxic capabilities can be increased by IL-12, a finding that may have clinical relevance.
引用
收藏
页码:571 / 579
页数:9
相关论文
共 50 条
  • [41] Effect of human umbilical cord blood CD34+progenitor cells transplantation in diabetic mice
    Hasein, Mona AbdElabry
    Attia, Fadia Mostafa
    Awad, Mohamed Mohy Eldin
    Abdelaal, Howedya Ahmed
    Elbarabary, Magady
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2011, 31 (02) : 113 - 117
  • [42] Nafamostat mesilate induces production of interleukin-12 and-18 in human peripheral blood mononuclear cells
    Katsuno, G
    Takahashi, HK
    Iwagaki, H
    Mizuno, K
    Mori, S
    Yoshino, T
    Nishibori, M
    Tanaka, N
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 98 (04) : 463 - 466
  • [43] Searching for unrelated donor hematopoietic stem cells: Availability and speed of umbilical cord blood versus bone marrow
    Barker, JN
    Krepski, TP
    DeFor, TE
    Davies, SM
    Wagner, JE
    Weisdorf, DJ
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (05) : 257 - 260
  • [44] Immunostimulatory effects of human recombinant interleukin-12 on peripheral blood mononuclear cells from normal dogs
    Phillips, BS
    Padilla, ML
    Dickerson, EB
    Lindstrom, MJ
    Helfand, SC
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1999, 70 (3-4) : 189 - 201
  • [45] Absolute density of different sources of hematopoietic progenitor cells: Bone marrow, peripheral blood stem cell and umbilical cord blood
    Araujo, Anelise Bergmann
    Angeli, Melissa Helena
    Salton, Gabrielle Dias
    Furlan, Juliana Monteiro
    Schmalfuss, Tissiana
    Rohsig, Liane Marise
    CYTOTHERAPY, 2017, 19 (01) : 128 - 130
  • [46] Ultrastructural features of CD34+ hematopoietic progenitor cells from bone marrow, peripheral blood and umbilical cord blood
    Deliliers, GL
    Caneva, L
    Fumiatti, R
    Servida, F
    Rebulla, P
    Lecchi, L
    De Harven, E
    Soligo, D
    LEUKEMIA & LYMPHOMA, 2001, 42 (04) : 699 - 708
  • [47] Proteome profiling of interleukin-12 treated human T helper cells
    Rosengren, AT
    Nyman, TA
    Lahesmaa, R
    PROTEOMICS, 2005, 5 (12) : 3137 - 3141
  • [48] Gene Therapy of Intracranial Glioma Using Interleukin 12-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells
    Ryu, Chung Heon
    Park, Sang-Hoon
    Park, Soon A.
    Kim, Seong Muk
    Lim, Jung Yeon
    Jeong, Chang Hyun
    Yoon, Wan-Soo
    Oh, Won-il
    Sung, Young Chul
    Jeun, Sin-Soo
    HUMAN GENE THERAPY, 2011, 22 (06) : 733 - 743
  • [49] Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage-cells into pseudomature lytic NK cells
    Bonanno, Giuseppina
    Mariotti, Andrea
    Procoli, Annabella
    Corallo, Maria
    Scambia, Giovanni
    Pierelli, Luca
    Rutella, Sergio
    BMC IMMUNOLOGY, 2009, 10 : 46
  • [50] Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model
    Stephen D Hess
    Nejat K Egilmez
    Junko Shiroko
    Richard B Bankert
    Cancer Gene Therapy, 2001, 8 : 371 - 377